Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 23,588 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the sale, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Najat Khan also recently made the following trade(s):

• On Monday, March 9th, Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.35, for a total value of $94,798.30.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded down $0.48 during trading on Friday, hitting $3.32. The stock had a trading volume of 26,796,919 shares, compared to its average volume of 17,402,092. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -2.77 and a beta of 1.04. The stock has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $3.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s quarterly revenue was down 56.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) EPS. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after buying an additional 7,407,606 shares during the period. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after buying an additional 3,771,357 shares in the last quarter. State Street Corp raised its holdings in Recursion Pharmaceuticals by 38.7% in the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after acquiring an additional 7,064,963 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock valued at $44,731,000 after purchasing an additional 1,310,695 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $23,473,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RXRX has been the subject of several analyst reports. Bank of America decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, Morgan Stanley raised their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.